Company / PP&E per Share
CRISPR Therapeutics AG PP&E per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E per Share
$1.35
FY2025
5-year range
$1.35 / $2.13
FY2021-FY2025
Trend
-19.3%
vs FY2024
Sector context
#42 of 193
Health Care
What the data says
CRISPR Therapeutics AG's pp&e per share of $1.35 is higher than 78% of companies in the Health Care sector (FY2025). PP&E per Share has declined for 3 consecutive years, from $2.13 in FY2022 to $1.35 in FY2025.
Based on SEC 10-K filings.
1.35 in FY2025 with a 5-year CAGR of +14.3%. Top quartile in the Health Care sector.
Declined from $1.94 to $1.35 over the past 2 years.
Health Care sector context is included.
PP&E per Share over time
Growth rates
- 3-Year CAGR
- -14.0%
- 5-Year CAGR
- +14.3%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 193This company $1.35 Sector average $18.71
▼
-92.8% below sector average
Key checks
Key Insights
- CRISPR Therapeutics AG's pp&e per share has declined for 3 consecutive years.
- In FY2025, pp&e per share decreased 19.3% year-over-year.
- Ranks #42 out of 193 companies in the Health Care sector.
- Peak pp&e per share was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.35 | -19.3% |
| FY2024 | $1.68 | -13.4% |
| FY2023 | $1.94 | -8.9% |
| FY2022 | $2.13 | +14.2% |
| FY2021 | $1.86 | +168.3% |
| FY2020 | $0.69 | +14.8% |
| FY2019 | $0.60 | +32.6% |
| FY2018 | $0.46 | -4.0% |
| FY2017 | $0.47 | -87.5% |
| FY2016 | $3.80 | +1342.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026